SummaryPatient-reported distress (PRD) has not been assessed in association with survival after radiation therapy (RT). This study aimed to evaluate the association between PRD level and survival after definitive RT by retrospectively reviewing a PRD questionnaire completed by patients undergoing definitive RT. The study showed that higher distress is associated with decreased survival.

Introduction {#sec1}
============

Patient-reported distress (PRD) among patients receiving radiation therapy (RT) has not been well characterized. The Institute of Medicine (IOM) and the National Comprehensive Cancer Network (NCCN) consider identifying and addressing psychosocial needs of cancer patients an increasingly important part of the standard of care in oncology,[@bib1], [@bib2] and the Commission on Cancer considers it an accreditation standard.[@bib3] The NCCN uses the term *distress* to describe psychosocial concerns. Distress associated with cancer is defined as an unpleasant emotional experience that interferes with the coping abilities of cancer patients. It can be psychologic (cognitive, behavioral, or emotional), spiritual, or social.[@bib4]

Distress is not always recognized. In a study of 143 physicians who provided cancer care and established the psychologic status of 2297 patients at 34 cancer centers, the physicians\' mean (standard deviation \[SD\]) sensitivity for identifying psychologic comorbidity was 29% (25%), and mean (SD) specificity was 85% (17%); 35% (14%) were misclassified with the wrong assessment.[@bib5] At our center, we have successfully implemented a program of standardized screening for distress. The IOM recommends caring for the whole person, including the patient\'s physical and psychologic well-being. Identifying PRD and decreasing it when possible can improve the patient\'s quality of life (QOL)[@bib6] and is consistent with the NCCN and IOM guidelines.

The primary objective of this retrospective study was to assess the correlation of PRD to patients\' survival after definitive RT. The secondary objective was to identify the main causes of distress among these patients. According to the concept that overall well-being of patients depends on both physical health and psychologic health, our hypothesis was that among oncology patients receiving definitive RT, the patients with higher levels of psychosocial distress have poorer survival after RT.

Methods and materials {#sec2}
=====================

Study patients and data collection {#sec2.1}
----------------------------------

A total of 678 consecutive patients who received definitive RT at our institution from April 2012 through May 2015 were included in this retrospective study. We included patients who had filled out a PRD questionnaire within 90 days before the start of RT and were at least 18 years old. Of the 678 patients, 637 (94.0%) completed the PRD questionnaire between 0 and 30 days before the start of RT, 24 (3.5%) completed the questionnaire between 31 and 60 days before the start of RT, and 17 (2.5%) completed the questionnaire between 61 and 90 days before the start of RT. We excluded 8 patients who had endocrine cancers because the number of patients was so small. Patients\' medical records were retrospectively assessed to extract information on age at RT, sex, primary cancer site and stage, RT dose, metastatic disease at the start of RT, chemotherapy at or before the start of RT, and surgery at or before the start of RT. There were no missing data, with the exception that data on metastatic disease at the start of RT were unavailable for 1 patient, and cancer stage was unavailable for a relatively large number of patients (167; 25%). The primary outcome measure of the study was overall survival after the start of RT.

PRD evaluation {#sec2.2}
--------------

Patients were asked to complete the PRD questionnaire, which contained 30 items related to possible causes of distress that might affect QOL ([Fig 1](#fig1){ref-type="fig"}). Each category was rated from 1 (no distress) to 5 (high distress). The PRD questionnaire was adapted from the Distress Thermometer and Problem List[@bib7] for clinical use at our institution in early 2012. The Distress Thermometer is a validated tool to assess psychosocial distress in cancer patients.[@bib7] Instead of using yes/no answers, our questionnaire used a scale from 1 to 5 for 30 possible causes of distress. It also included a drawing of a distress thermometer, as with the NCCN Distress Thermometer,[@bib2] to measure the patient\'s overall distress level, with a range from 0 (no distress) to 10 (extreme distress). This 11-point scale provided our primary measure of PRD (called *PRD level*) and was the measure that we used for evaluating the association between patient distress level and survival after RT.Figure 1Patient-reported distress form. (data from National Comprehensive Cancer Network[@bib2] and Jacobsen et al[@bib7])

Statistical analysis {#sec2.3}
--------------------

Continuous variables were summarized with the sample median and range. Categorical variables were summarized with the number and percentage of patients. Responses to the 30 possible causes of distress in the PRD questionnaire were summarized with the sample mean and with the number and percentage of patients for each response. PRD level was considered as a continuous variable to evaluate a linear trend and as a categorical variable with 3 PRD levels (low, 0-3; moderate, 4-6; and high, 7-10) to evaluate for a potential nonlinear association. Baseline characteristics were compared between patients with low, moderate, or high PRD levels with a Kruskal-Wallis rank sum test or the Fisher exact test. The Kaplan-Meier method was used to estimate survival after the start of RT, where censoring occurred on the date of latest follow-up. Associations between baseline patient characteristics and survival after the start of RT were evaluated with univariable (ie, unadjusted) Cox proportional hazards regression models. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. The association of PRD level (both as a continuous variable and as a categorical variable) with survival after the start of RT was evaluated with univariable and multivariable Cox proportional hazards regression models. Multivariable models were adjusted for all baseline variables that did not have large amounts of missing data, which included age, sex, primary cancer site, RT dose, metastatic disease at the start of RT, chemotherapy at or before the start of RT, and surgery at or before the start of RT. Stage was not adjusted for because of the extent of missing data. HRs and 95% CIs were estimated. *P* values of .05 or less were considered statistically significant. All statistical analyses were performed with SAS software (version 9.2; SAS Institute Inc) and R statistical software (version 2.14.0; R Foundation for Statistical Computing).

Results {#sec3}
=======

Patient characteristics according to PRD level (low, moderate, or high) are compared in [Table 1](#tbl1){ref-type="table"}. Differences between the 3 distress level groups were significant for age (*P* = .003), sex (*P* = .011), and primary cancer site (*P* \< .001). Specifically, patients with lower reported levels of distress tended to be older and male with a primary cancer site in the genitourinary tract or skin. Differences among the 3 distress level groups were not significant for stage (*P* = .19), dose (*P* = .86), metastatic disease (*P* = .14), chemotherapy (*P* = .65), or surgery (*P* = .56).Table 1Patient characteristics according to distress level at the start of RT[a](#tbl1fna){ref-type="table-fn"}VariableLow distress, 0-3 (n = 295)[b](#tbl1fnb){ref-type="table-fn"}Moderate distress, 4-6 (n = 222)[b](#tbl1fnb){ref-type="table-fn"}High distress, 7-10 (n = 161)[b](#tbl1fnb){ref-type="table-fn"}*P* value[c](#tbl1fnc){ref-type="table-fn"}Age at start of RT, y68 (29-97)66 (27-90)63 (23-93).003Male161 (54.6)98 (44.1)67 (41.6).011Primary cancer site\<.001 Head and neck53/147 (36.1)60/147 (40.8)34/147 (23.1) Breast58/145 (40.0)50/145 (34.5)37/145 (25.5) GI tract44/96 (45.8)31/96 (32.3)21/96 (21.9) Genitourinary tract51/74 (68.9)11/74 (14.9)12/74 (16.2) Lung28/62 (45.2)17/62 (27.4)17/62 (27.4) Brain or CNS14/41 (34.2)11/41 (26.8)16/41 (39.0) Soft tissue or bone11/37 (29.7)15/37 (40.5)11/37 (29.7) Gynecologic site12/35 (34.3)15/35 (42.9)8/35 (22.9) Skin19/26 (73.1)5/26 (19.2)2/26 (7.7) Lymph node5/15 (33.3)7/15 (46.7)3/15 (20)Stage.19 0 or 156/215 (26.0)55/173 (31.8)41/123 (33.3) 269/215 (32.1)39/173 (22.5)27/123 (22.0) 348/215 (22.3)47/173 (27.2)26/123 (21.1) 442/215 (19.5)32/173 (18.5)29/123 (23.6)Dose, cGy5040 (1000-7920)5,82 (540-7920)5040 (1400-7000).86Metastatic at start of RT[d](#tbl1fnd){ref-type="table-fn"}25 (8.5)28 (12.6)11 (6.8).14Chemotherapy at or before start of RT156 (52.9)126 (56.8)90 (55.9).65Surgery at or before start of RT200 (67.8)160 (72.1)110 (68.3).56[^1][^2][^3][^4][^5]

Median length of follow-up after the start of definitive RT was 14.1 months (range, 8 days to 39.2 months); 111 patients (16%) died. Kaplan-Meier estimated survival at 6 months, 1 year, and 2 years after the start of RT was 95% (95% CI, 93-97), 87% (95% CI, 85-90), and 78% (95% CI, 74-82), respectively. To better understand how the characteristics shown in [Table 1](#tbl1){ref-type="table"} might act as confounding variables when assessing the relationship between PRD level and survival, we next examined the associations of these characteristics and survival after definitive RT ([Table 2](#tbl2){ref-type="table"}). The following associations with survival after RT were significant: age (HR \[per 10-year increase\], 1.26; *P* = .003); male sex (HR, 1.63; *P* = .012); chemotherapy at or before the start of RT (HR, 2.38; *P* \< .001); and surgery at or before the start of RT (HR, 0.57; *P* = .004). Compared with survival for stage 0 or 1 patients, survival was significantly worse for patients with cancer in stage 2 (HR, 3.92; *P* = .001); stage 3 (HR, 5.73; *P* \< .001); or stage 4 (HR, 4.37; *P* \< .001). Survival after RT was significantly different according to primary cancer site (*P* \< .001); compared with the most common site of head and neck, survival was significantly better for patients with breast cancer (HR, 0.06; *P* \< .001) and genitourinary cancer (HR, 0.04; *P* = .002). No notable associations with survival after RT were noted for dose (*P* = .91) or metastatic disease (*P* = .58).Table 2Associations between baseline patient characteristics and survival after definitive RT[a](#tbl2fna){ref-type="table-fn"}VariableHR[b](#tbl2fnb){ref-type="table-fn"} (95% CI)*P* valueAge at start of RT (10-y increase)1.26 (1.08-1.47).003Male1.63 (1.11-2.40).012Primary cancer site\<.001 Head and neck1.00 (reference)NA Breast0.06 (0.01-0.24)\<.001 GI tract0.94 (0.56-1.59).83 Genitourinary tract0.04 (0.01-0.32).002 Lung1.47 (0.85-2.56).17 Brain or CNS1.23 (0.63-2.43).55 Soft tissue or bone0.44 (0.15-1.23).12 Gynecologic site0.71 (0.30-1.69).44 Skin1.51 (0.67-3.41).32 Lymph node0.47 (0.11-1.98).31Stage\<.001 0 or 11.00 (reference)NA 23.92 (1.69-9.06).001 35.73 (2.53-12.98)\<.001 44.37 (1.86-10.29)\<.001Dose (1000-cGy increase)1.01 (0.86-1.18).91Metastatic at start of RT1.19 (0.64-2.22).58Chemotherapy at or before start of RT2.38 (1.56-3.62)\<.001Surgery at or before start of RT0.57 (0.39-0.84).004[^6][^7][^8]

Associations between PRD and survival after definitive RT are shown in [Table 3](#tbl3){ref-type="table"}. PRD level as a continuous variable showed a significant association with survival in both univariable analysis (HR, 1.34; *P* = .007) and multivariable analysis after adjusting for age, sex, primary cancer site, dose, metastatic disease at the start of RT, chemotherapy at or before the start of RT, and surgery at or before the start of RT (HR, 1.39; *P* = .004). PRD level as a categorical variable in univariable analysis, in comparison to patients with a low-distress level, showed significantly poorer survival after RT for patients with moderate distress (HR, 1.58; *P* = .042) but not for patients in the smaller high-distress group (HR, 1.42; *P* = .15). These results were similar in multivariable analysis ([Table 3](#tbl3){ref-type="table"}); however, because the magnitude of difference in survival in comparison to the low-distress patients was relatively similar between the moderate- and high-distress groups, as evidenced by the relatively similar HRs (1.58 and 1.42, respectively), we combined the moderate- and high-distress groups and examined the association with survival after RT. As shown in [Table 3](#tbl3){ref-type="table"}, patients with either a moderate or high distress level had significantly poorer survival than patients with low distress in both univariable analysis (HR, 1.51; *P* = .042) and multivariable analysis (HR, 1.57; *P* = .034). Survival after the start of RT is shown for the 3 distress level groups in [Figure 2](#fig2){ref-type="fig"}.Figure 2Survival after definitive radiation therapy according to patient-reported distress. Patients rated their distress level from 0 (no distress) to 10 (extreme distress). Low distress indicates ratings from 0 through 3; moderate distress, from 4 through 6; and high distress, from 7 through 10.Table 3Associations between PRD and survival after definitive RT[a](#tbl3fna){ref-type="table-fn"}PRD levelSurvival after RT (95% CI)Univariable analysisMultivariable analysis[b](#tbl3fnb){ref-type="table-fn"}1 y after RT2 y after RTHR (95% CI)*P* valueHR (95% CI)*P* valueAs a continuous variable 3-unit increaseNANA1.34 (1.08-1.65).0071.39 (1.11-1.74).004As a categorical variable.11[c](#tbl3fnc){ref-type="table-fn"}.10[c](#tbl3fnc){ref-type="table-fn"} Low distress, 0-3 (n = 295)90% (86%-94%)83% (77%-89%)1.00 (reference)NA1.00 (reference)NA Moderate distress, 4-6 (n = 222)84% (79%-90%)73% (66%-81%)1.58 (1.02-2.44).0421.62 (1.03-2.56).038 High distress, 7-10 (n = 161)87% (81%-93%)74% (65%-84%)1.42 (0.88-2.30).151.49 (0.90-2.48).12 Moderate or high distress, 4-10 (n = 383)85% (81%-89%)74% (68%-80%)1.51 (1.02-2.24).0421.57 (1.03-2.38).034[^9][^10][^11][^12]

[Figure 3](#fig3){ref-type="fig"} shows mean values for the 29 individual distress items from the PRD questionnaire ([Fig 1](#fig1){ref-type="fig"}; [eTable 1](#appsec1){ref-type="sec"}, available as supplementary material online only at [www.practicalradonc.org](http://www.practicalradonc.org){#interref0010}). The top 5 causes of distress were "How I feel during treatment" (mean, 2.49); "Fatigue" (mean, 2.39); "Out-of-pocket medical costs" (mean, 2.25); "Pain that affects my daily functioning" (mean, 2.24); and "Sleep difficulties" (mean, 2.23). The least worrisome concerns were "Spirituality" (mean, 1.34); "Controlling my anger" (mean, 1.40); "Transportation to treatment" (mean, 1.40); "Housing during treatment" (mean, 1.41); and "A loved one relying on me for their physical care" (mean, 1.42).Figure 3Mean values of responses to patient-reported distress items. Patients used each item to complete the statement "I am concerned about..." on a 5-point scale from 1 ("Not at all") to 5 ("Very much").

Discussion {#sec4}
==========

The results of this study provide the first evidence that a higher level of patient distress before and during RT is associated with a poorer outcome after RT. Specifically, patients who had a score of 4 or more on the overall PRD level questionnaire had a 1.5-fold increased risk of death after RT compared with patients with lower scores. This translated into a 2-year survival rate of 74%, which is about 10% less than that for patients with lower scores (83%). Importantly, this finding was independent of key characteristics, including age, sex, primary cancer site, RT dose, metastatic disease, chemotherapy, and surgery; however, the possibility that other unmeasured variables influenced these results must certainly be acknowledged.

Distress screening and interventions should be implemented in all oncology centers to assess, anticipate, and alleviate suffering of patients and to improve QOL and survival. At our institution, a distress screening consultation with a certified social worker is warranted if patients rate any of the 30 items as 4 or more or if they rate their overall distress as 8 or more. A lower distress screening threshold protocol should be implemented.

Psychosocial distress related to RT has been a well-established association since the early 1980s, when studies showed that cancer patients receiving RT are at more risk for distress and the complications that might arise from RT.[@bib8], [@bib9] Multiple studies have suggested that routine distress screening for patients undergoing RT is vital.[@bib10], [@bib11] The regular use of screening leads to improved communication between patients and their health care providers.[@bib12] However, PRD is not well appreciated by all medical providers: some consider it an inadequate and unfeasible screening tool, contrary to the patients\' perspectives, which have shown moderate satisfaction with the screening process.[@bib13], [@bib14], [@bib15], [@bib16] When cancer is diagnosed, psychosocial support should be initiated through an integrated medical collaboration.[@bib17], [@bib18] Distress might increase during multiple cancer treatments and might peak approximately 2 weeks after the start of RT.[@bib19] Another study suggested that other complications related to treatment, such as anxiety and depression, are highest before treatment and diminish with treatment, followed by an increase in distress symptoms up to 1 year after completion of RT.[@bib20] This suggests that longer follow-up is needed to monitor the psychosocial status of those patients.

Psychosocial function usually decreases in about one-third of patients receiving RT who experience distress.[@bib21] Consequently, multiple studies have suggested that short-term RT complications such as fatigue subside to baseline by week 27 after RT, and management of the patients is indicated for boosting patient self-esteem and therefore QOL.[@bib22], [@bib23] The combination of distress screening and distress management resources availability are essential for mounting a good response to the psychosocial complications of cancer treatment.[@bib24]

Several studies recommended different approaches for managing distress while receiving RT. Methods such as mindfulness-based intervention, yoga, and listening to music have been shown to improve overall QOL by reducing stress level and hence cortisol level.[@bib25], [@bib26], [@bib27] Other techniques, such as Web-based cognitive behavioral therapy, may be more convenient for patients than traditional cognitive behavioral therapy.[@bib28]

The top 5 causes of distress in our sample were mostly related to RT short-term side effects that would subside with time (eg, fatigue, pain, sleeping difficulties) rather than long-term complications that would have a greater effect on QOL.[@bib29], [@bib30] Other studies have suggested that fatigue might persist and cause a chronic complication.[@bib31] Medical cost was 1 of the top 3 concerns of patients, indicating the need to evaluate this area proactively and, when possible, to inform patients of available additional resources (eg, identifying a more affordable pharmacy through an Internet site).[@bib32]

The 5 least distressing components in our sample were related to how patients dealt with the logistics of receiving RT, which included transportation and housing. Spirituality was identified as the least likely area to be affected by RT. Cancer patients use spirituality and faith to deal with the stress of coping with cancer.[@bib33] Sources of PRD likely vary in different patient populations.

The main limitation of the study is the retrospective design. Another noteworthy limitation is the lack of staging information for approximately 25% of the patients in our database. As a result, we could not adjust for stage in our multivariable analysis to directly address any confounding potential that it might have. As expected, survival was markedly worse for patients with higher stage cancer; however, stage did not differ significantly among the 3 distress level groups (*P* = .19), and therefore it has limited confounding potential and would likely not alter the results of the association analysis involving PRD level and survival after RT.

Conclusion {#sec5}
==========

To the best of our knowledge, this is the first study to show that an elevated level of PRD in patients receiving definitive RT is associated with poorer outcome in the form of lower survival after treatment. PRD and survival for patients who rated their overall distress level lower than 4 had better survival than patients with higher distress levels. Timely identification and early intervention may mitigate the consequences of distress. Distress screening guidelines should be implemented for patients receiving definitive RT. Interventions for those at higher levels of distress should be further evaluated and assessed for effectiveness in reducing PRD. Radiation oncologists and all cancer specialists need to develop targeted interventions to better meet the unique needs of each patient. Further studies are needed to assess whether targeted distress intervention would help to decrease the degree of PRD and improve survival.

Supplementary data {#appsec1}
==================

eTable 1

Sources of support: This study was funded by the Mayo Clinic College of Medicine, which had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the manuscript for publication.

Conflicts of interest: None.

Supplementary material for this article ([http://dx.doi.org/10.1016/j.prro.2017.03.004](10.1016/j.prro.2017.03.004){#intref0015}) can be found at [www.practicalradonc.org](http://www.practicalradonc.org){#intref0020}.

[^1]: CNS, central nervous system; GI, gastrointestinal; RT, radiation therapy.

[^2]: Patients rated their distress level from 0 (no distress) to 10 (extreme distress).

[^3]: Continuous data are presented as median (range). Categorical data are presented as number of patients (percentage of sample).

[^4]: *P* values are from a Kruskal-Wallis rank sum test or the Fisher exact test.

[^5]: Metastatic disease information was unavailable for 1 patient.

[^6]: CI, confidence interval; CNS, central nervous system; GI, gastrointestinal; HR, hazard ratio; NA, not applicable; RT, radiation therapy.

[^7]: HRs, 95% CIs, and *P* values were determined from unadjusted Cox proportional hazards regression models.

[^8]: HRs correspond to the increase in parentheses for continuous variables and to the presence of the given characteristic for categorical variables.

[^9]: CI, confidence interval; HR, hazard ratio; NA, not applicable; PRD, patient-reported distress; RT, radiation therapy.

[^10]: HRs, 95% CIs, and *P* values were determined from Cox proportional hazards regression models.

[^11]: Multivariable models were adjusted for age, sex, primary cancer site, RT dose, metastatic disease at the start of RT, chemotherapy at or before the start of RT, and surgery at or before the start of RT.

[^12]: Test of overall difference.
